Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases
|04/09/2018||Posted by BusinessMediaguide.Com under General World News||
- Novartis is acquiring gene therapy company AveXis for $8.7 billion.
- AveXis is working on a gene therapy for spinal muscular atrophy, a rare genetic condition that affects muscle movement in children and is the leading genetic cause of mortality in infants.
- It’s part of a wave of big bets in gene therapy, a cutting-edge area of science that has had some big advancements over the past year.
Novartis said on Monday that it’s acquiring rare disease drugmaker AveXis for $8.7 billion.
AveXis is working on a treatment for spinal muscular atrophy (SMA), a rare genetic condition that affects muscle movement. It’s the read more >>>